BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitusTherapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
2
Theodosios D Filippatos, Moses S Elisaf. Safety considerations with fenofibrate/simvastatin combinationExpert Opinion on Drug Safety 2015; 14(9): 1481 doi: 10.1517/14740338.2015.1056778
3
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf, George Liamis. Acid-base and electrolyte disorders associated with the use of antidiabetic drugsExpert Opinion on Drug Safety 2017; 16(10): 1121 doi: 10.1080/14740338.2017.1361400
4
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos, Moses S. Elisaf. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular diseaseMetabolism 2012; 61(7): 906 doi: 10.1016/j.metabol.2011.12.002
5
Theodosios D Filippatos, Vasilios G Athyros, Moses S Elisaf. The pharmacokinetic considerations and adverse effects of DDP-4 inhibitorsExpert Opinion on Drug Metabolism & Toxicology 2014; 10(6): 787 doi: 10.1517/17425255.2014.907274
6
Vasilios Tsimihodimos, Theodosios D. Filippatos, Moses S. Elisaf. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversiesExpert Opinion on Drug Metabolism & Toxicology 2017; 13(4): 399 doi: 10.1080/17425255.2017.1258055
7
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S. Elisaf. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypothesesPostgraduate Medicine 2019; 131(2): 82 doi: 10.1080/00325481.2019.1581971